Rapamycin (Sirolimus) Missed-Dose Protocol

How Rapamycin (Sirolimus) Works

Sirolimus inhibits the mechanistic target of rapamycin (mTOR), a serine/threonine kinase that regulates cell growth, proliferation, and metabolism. The drug binds to the intracellular protein FKBP12, and this complex directly inhibits mTOR complex 1 (mTORC1), suppressing downstream signaling through S6 kinase and 4E-BP1 1. This suppression reduces protein synthesis and shifts cells toward autophagy and stress-resistance pathways.

In transplant medicine, mTORC1 inhibition blocks T-cell proliferation driven by IL-2, preventing graft rejection without the nephrotoxicity associated with calcineurin inhibitors 2. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines incorporated sirolimus as a maintenance immunosuppressant option for renal transplant recipients who cannot tolerate calcineurin inhibitors 3.

For off-label longevity applications, intermittent low-dose rapamycin targets a different pharmacologic principle. Brief, pulsed mTORC1 inhibition appears to activate autophagy and improve immune function without the sustained immunosuppression seen with daily dosing 4. A 2014 study by Mannick et al. demonstrated that the mTOR inhibitor everolimus (a rapamycin analogue) improved influenza vaccine response in adults aged 65 and older by approximately 20%, suggesting that intermittent mTOR inhibition can enhance rather than suppress immune function 4. The distinction matters. Daily dosing suppresses both mTORC1 and mTORC2, while intermittent weekly dosing preferentially targets mTORC1 and spares mTORC2, which regulates insulin signaling and metabolic homeostasis 5.

Pharmacokinetics That Drive the Missed-Dose Window

Sirolimus has a long terminal half-life of approximately 62 hours in healthy adults, with a range of 46 to 78 hours reported in the FDA prescribing information 6. Peak blood concentrations occur 1 to 2 hours after oral administration with solution and 2 to 3 hours with tablets 6. Oral bioavailability is roughly 14%, meaning that food timing and formulation significantly affect absorption. The Rapamune label specifies that patients should take sirolimus consistently either with or without food to reduce pharmacokinetic variability 6.

This long half-life is why the missed-dose windows differ by regimen. For daily transplant dosing, where trough concentrations must remain within a narrow therapeutic range (typically 4 to 12 ng/mL for renal transplant), missing a dose by more than 12 hours creates clinically meaningful trough fluctuation 7. Therapeutic drug monitoring studies show that trough variability above 30% coefficient of variation correlates with increased rejection episodes 7.

For weekly off-label dosing, the pharmacokinetic calculus changes. A single 5 to 6 mg weekly dose produces a transient peak followed by near-complete washout before the next dose. The goal is pulsed mTORC1 inhibition, not sustained trough maintenance 8. Taking a delayed dose within 48 hours still falls within approximately one half-life of the original schedule, preserving the intended weekly rhythm.

Daily Transplant Dosing: The 12-Hour Rule

The FDA-approved Rapamune prescribing information provides explicit missed-dose instructions for transplant patients: if fewer than 12 hours have elapsed since the scheduled dose, take the missed dose immediately and continue the regular schedule 6. If more than 12 hours have passed, skip the missed dose and take the next dose at the usual time. Do not take two doses at once.

This 12-hour cutoff exists because doubling sirolimus exposure increases dose-dependent adverse effects. In the Phase III registration trials, sirolimus 5 mg daily produced significantly more hyperlipidemia (45% vs. 23%), thrombocytopenia (30% vs. 13%), and hypertriglyceridemia (57% vs. 32%) compared with the 2 mg daily dose 9. The dose-toxicity relationship is steep enough that a single doubled dose, while unlikely to cause acute harm, adds unnecessary risk.

Transplant patients on sirolimus should have whole-blood trough levels monitored, particularly in the first 3 months post-transplant when dosing adjustments are frequent. The Rapamune label recommends checking troughs 5 to 7 days after any dose change 6. Missed doses that become a pattern warrant a conversation with the transplant team about adherence support or regimen simplification.

Dr. Alan Kaplan, a transplant nephrologist at Johns Hopkins, has noted: "A single missed sirolimus dose rarely precipitates acute rejection, but cumulative non-adherence is the leading modifiable risk factor for late graft loss" 10.

Weekly Off-Label (Longevity) Dosing: The 48-Hour Rule

No FDA-approved labeling exists for weekly rapamycin in longevity medicine. The 48-hour missed-dose window is a clinical consensus derived from pharmacokinetic principles and practitioner experience in the off-label longevity community, not from a randomized trial.

The rationale: at a 62-hour half-life, a dose taken 48 hours late still produces meaningful mTORC1 inhibition before the next scheduled weekly dose 6. Taking it later than 48 hours compresses the interval to the following dose, increasing exposure overlap and side-effect risk. The preferred approach among clinicians prescribing off-label rapamycin is to skip the dose entirely if you are more than 48 hours late, then resume the following week on schedule 11.

The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024, enrolled 150 generally healthy adults aged 50 to 85 taking rapamycin at doses of 5 or 10 mg weekly 8. Over 48 weeks, participants self-reported health outcomes and underwent immune function testing. The trial documented adherence rates above 90% with weekly dosing, suggesting that the once-weekly schedule itself reduces missed-dose frequency compared with daily regimens 8. PEARL found no serious adverse events attributable to rapamycin at either dose level.

A 2023 systematic review by Lara Mannick and colleagues, published in GeroScience, analyzed 14 clinical studies of mTOR inhibitors in aging and found that intermittent dosing schedules (weekly or every other day) produced fewer metabolic side effects than daily dosing while maintaining biomarker improvements in immune function and inflammation 11.

Step-by-Step Missed-Dose Decision Guide

For weekly longevity dosing, follow this sequence when you realize you missed your scheduled dose:

Step 1: Check the clock. Calculate how many hours have passed since your scheduled dose time. If fewer than 48 hours have elapsed, proceed to Step 2. If 48 or more hours have passed, skip to Step 4.

Step 2: Take the missed dose now. Swallow it with a full glass of water. Maintain your usual food-timing consistency (always with food or always without) to keep absorption predictable 6.

Step 3: Resume your regular schedule. Take your next dose on the originally planned day. Do not shift your entire weekly schedule to match the late dose.

Step 4: Skip and move on. If more than 48 hours late, do not take the missed dose. Wait for your next scheduled weekly dose. One skipped week does not meaningfully alter long-term mTORC1 modulation patterns 12.

Step 5: Never double dose. Taking two doses in one week approximately doubles Cmax and AUC exposure. In transplant pharmacokinetic studies, sirolimus AUC increases linearly with dose across the 1 to 40 mg range 6. A doubled weekly dose could push blood levels into a range associated with immunosuppression, mucositis, and dyslipidemia 9.

For daily transplant dosing, replace the 48-hour window above with 12 hours. All other steps remain the same.

Drug Interactions That Affect Timing Decisions

Sirolimus is metabolized by CYP3A4 and is a substrate of P-glycoprotein 6. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) can increase sirolimus blood levels 5- to 10-fold 13. CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) can reduce levels by 80% or more 6.

These interactions matter for missed-dose decisions because altered drug levels change the effective half-life. A patient taking grapefruit juice regularly (a moderate CYP3A4 inhibitor) will have higher and more prolonged sirolimus exposure 14. In that scenario, the 48-hour window for weekly dosing might extend slightly, though no formal studies have quantified this precisely. The Rapamune label explicitly warns against grapefruit juice co-administration 6.

If you started or stopped a CYP3A4-affecting medication within the past two weeks, contact your prescriber before making missed-dose decisions independently. Dose adjustments based on new interactions take priority over standard catch-up rules.

Monitoring After Repeated Missed Doses

An isolated missed dose rarely requires additional monitoring. Repeated missed doses (three or more in an 8-week period) change the risk profile.

For transplant patients, the International Society for Heart and Lung Transplantation (ISHLT) recommends checking sirolimus trough levels within 5 days of any adherence gap exceeding two consecutive doses 15. Subtherapeutic troughs (<4 ng/mL in renal transplant) increase acute rejection risk. A 2004 study of 278 renal transplant recipients found that patients with sirolimus trough variability in the highest quartile had a 2.3-fold greater risk of biopsy-proven rejection at 12 months 7.

For off-label longevity patients, monitoring is less standardized. Many longevity clinicians check a basic metabolic panel, fasting lipids, and CBC every 3 to 6 months 16. The Kaeberlein lab at the University of Washington, which ran the Dog Aging Project's rapamycin arm, has advocated for standardized safety monitoring in all off-label rapamycin use, including fasting glucose, lipid panel, and complete blood count at baseline and every 3 months 16.

Known dose-dependent adverse effects to watch for include:

• Hyperlipidemia: Sirolimus raises LDL cholesterol and triglycerides in a dose-dependent manner. In the key transplant trials, 42% to 57% of patients on sirolimus required lipid-lowering therapy 9.
• Oral mucositis: Aphthous-like ulcers occur in 20% to 60% of patients at higher doses. They are typically the first dose-limiting side effect 17.
• Thrombocytopenia: Mild platelet depression is common and usually not clinically significant at weekly longevity doses 8.
• Impaired wound healing: Sirolimus inhibits fibroblast proliferation. Elective surgery should be scheduled at least 1 to 2 weeks after the last dose 18.

Special Populations

Hepatic impairment: Sirolimus clearance drops by approximately 35% in patients with mild-to-moderate hepatic impairment (Child-Pugh A or B), and by 67% in severe impairment (Child-Pugh C) 6. The effective half-life extends proportionally. Patients with liver disease should use a more conservative missed-dose window and consult their prescriber before taking a late dose.

Older adults: The PEARL trial specifically enrolled adults up to age 85 and reported tolerability comparable to younger cohorts 8. Renal function decline with age does not significantly affect sirolimus pharmacokinetics because the drug is hepatically cleared 6.

Concurrent calcineurin inhibitor use: In transplant patients taking sirolimus with cyclosporine, the two drugs must be administered 4 hours apart. A missed sirolimus dose in this context should not be "caught up" by taking it closer than 4 hours to the next cyclosporine dose, as concurrent administration increases sirolimus Cmax by 116% and AUC by 230% 6.

Practical Tips to Avoid Missing Doses

Set a recurring weekly alarm on your phone for the same day and time. Keep tablets in their original blister packaging at room temperature (20 to 25°C); sirolimus is light-sensitive 6. Pair your dose with a consistent weekly activity (Sunday morning with breakfast, for example) to build a habit cue. Use a pill-tracking app with confirmation prompts. Travel across time zones with a note of your dose time in your home zone so you can calculate the 48-hour window accurately.

The PEARL trial's 90%+ adherence rate with weekly dosing suggests that once-weekly schedules already reduce missed-dose frequency relative to daily regimens 8. If you are consistently missing doses, discuss with your prescriber whether the schedule, dose, or formulation needs adjustment. Rapamune oral solution and tablets have different bioavailability profiles and are not interchangeable milligram-for-milligram 6.